Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) have been given an average recommendation of “Hold” by the twenty ratings firms that are currently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, thirteen have issued a hold recommendation and five have given a buy recommendation to […]